Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Cedars-Sinai Medical Center
Information provided by (Responsible Party):
Noel Bairey Merz, Cedars-Sinai Medical Center Identifier:
First received: December 12, 2007
Last updated: May 6, 2013
Last verified: May 2013

December 12, 2007
May 6, 2013
January 2005
December 2015   (final data collection date for primary outcome measure)
estrogen deficiency of hypothalamic (central brain) origin [ Time Frame: Baseline and Exit Visits ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00572858 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women
Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

For unexplained reasons, young premenopausal women with heart disease have twice the rate of death compared to men of the same age. Animal experiments have shown that stress can reduce ovary function in females monkeys due to reductions in brain hormones. This stress and reduced brain hormone levels lead to low estrogen levels and can cause menstrual cycles to become irregular, leading to reductions in fertility. These monkeys are also more likely to develop heart disease. In order, to better understand this relationship the investigators would like to study estrogen levels in premenopausal women with heart disease.

Premenopausal women who have recently undergone a study of their coronary (heart) arteries will have their blood hormone levels measured over one menstrual cycle. The investigators will correlate the blood hormone levels with coronary angiography results and with other markers of heart disease, such as a test that uses noninvasive, painless ultrasound waves to study the thickness of the arteries in the neck (carotid arteries). In addition blood cholesterol levels, blood sugar levels and other blood tests have been shown to correlate with heart disease will be measured.

Another aim of the study is to evaluate a potential link between environmental stress and hormone levels. Each patient will be given multiple questionnaires to evaluate stress, anxiety and depression and the investigators will be measuring the stress hormone (cortisol) levels in saliva for additional information.

The results of the study will further explore a possible link between low estrogen levels and heart disease in young premenopausal women and help pave the way for larger research studies to define better ways of preventing heart disease in these women.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   None Retained

Blood Hormone draw for FSH, E2; Urine Pregnancy test; Fasting lipid (cholesterol) panel, fasting insulin and fasting blood glucose levels; Reproductive hormones (FSH, LH, E1, E2, bioE2, PO, freeT, SHBG, DHEA-S); Plasma levels of inflammatory and endothelial function markers including but not limited to hsCRP, serum amyloid, endothelin-1, and ELAM; Fasting Salivary Cortisol (stress hormone).

Non-Probability Sample

Premenopausal Women

Estrogen Deficiency
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Premenopausal by WISE criteria
  • English speaking (for the purposes of complete psychosocial assessment)
  • Able to give informed consent
  • Clinically-indicated coronary angiography within the last 24 months prior to enrollment with no interim change in symptoms, hospitalization, or events.
  • Non-English speaking patients will be consented but will not undergo psychosocial assessment as part of the study.

Exclusion Criteria:

  • Pregnant or intention of becoming pregnant during study period.
  • Current hormonal therapy (oral contraceptives, hormone replacement therapy, designer estrogens or phytoestrogens)
  • History of bilateral salpingoophorectomy
up to 55 Years
Contact: Jo-Ann Eastwood, PhD 310-423-9680
Contact: Ying Mou, PhD 3102487669
United States
IRB 6326
Noel Bairey Merz, Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Not Provided
Principal Investigator: Noel Bairey-Merz, MD Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP